(Elverum, January 19th, 2018) Investinor, funded by the Norwegian government, invests 25 MNOK in the pharmaceutical development and manufacturing company Curida. The company has raised in total 75 MNOK. Canica and Klaveness Marine invested 25 MNOK each in December 2017.
Curida is an exciting pharma company with global ambitions, and we have worked closely with them over the last 12 months. Along with the other owners, we will bring capital and knowledge to contribute to further development of Curida. We see a great potential in the company, Haakon H. Jensen, Managing Director of Investinor, says.
Chairman Per S. Thoresen and CEO Leif Rune Skymoen are very pleased with the completion of the financial process. The investment will drive further development of Curida operations and strengthen international sales activities. Curida also acquired the Norwegian pharmaceutical manufacturer Ås produksjonslab earlier this month.
The recent events have strengthened Curida. We are pleased to have Investinor joining the team, as it is a professional investor in growth companies, Thoresen says.
The investors joining the Curida team are professional and strong, and will help the company take a leading position in the contract development and manufacturing market in Norway and internationally, Corporate Director Nils Hovtun of SpareBank 1 Markets says.